RACHEL REED: Open Payments
NPI 1568076669 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$266 in 10 payments from 8 companies in 2025. Trend: 2023 $751 · 2024 $680 · 2025 $266
Food & beverage: $266
| Company | Payments | Amount |
|---|---|---|
| Organogenesis Inc. | 2 | $82 |
| Novartis Pharmaceuticals Corporation | 2 | $44 |
| Travere Therapeutics, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| GENZYME CORPORATION | 1 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Novo Nordisk Inc | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $17 |
Products named: NUSHIELD, Fabhalta, JYNARQUE, FABRAZYME, TARPEYO, Ozempic, BENLYSTA, PURAPLY WOUND MATRIX.
Industry payments across KS — which companies pay providers there.
